$lly Archives - Vista Partners LLC | HomeVista Partners LLC

GLP-1s, Hairlines, and the Almost-Pumpers: Why Modular Medical May Be Ready for Its Close-Up -( $LLY $MODD )

by John F. Heerdink, Jr. 20 hours ago 57Views 0Likes

At this point, glucagon-like peptide-1 drugs, or GLP-1s, have become the market’s favorite lifestyle macro-theme, credited with trimming waistlines, lowering A1Cs, and supposedly reshaping everything from snack aisles to airplane seat designs. Yet in 2026, a new subplot is stealing some headlines:…

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

by John F. Heerdink, Jr. 4 days ago 245Views 0Likes

Eli Lilly’s (LLY) latest AI move reads less like a side project and more like a statement: the drugmaker is quietly trying to turn biology into software—and it just hired Profluent as one of its lead engineers. Lilly Bets Big On AI-Authored…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. April 20, 2026 129Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

Diabesity’s New Plus‑One: FDA Gives Green Light to Modular Medical’s Pivot Patch Pump -( $MODD $LLY $NVO )

by John F. Heerdink, Jr. April 9, 2026 447Views 0Likes

Modular Medical’s (NASDAQ: MODD) latest regulatory milestone upgrades the narrative: the company has now secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. Pivot Patch Pump Gets…

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

by John F. Heerdink, Jr. April 8, 2026 275Views 0Likes

The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…

The Big Mac Meets the Skinny Pill: How McDonald’s and Eli Lilly Are Sharing the Same Consumer -( $LLY $MCD )

by John F. Heerdink, Jr. February 12, 2026 469Views 0Likes

McDonald’s (MCD) has handled low-carb fads, kale revolutions, and the brief reign of cauliflower rice, but its newest rival comes with a prescription label and a co-pay. GLP-1 weight-loss medicines—from injectables like Eli Lilly’s (LLY) Mounjaro and Zepbound to the next wave…

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

by John F. Heerdink, Jr. February 9, 2026 363Views 0Likes

Eli Lilly (LLY) has once again muscled its way to the top of the healthcare league tables, with its stock climbing as investors double down on the idea that obesity drugs are less a fad and more a new asset class. The…

Tag: $lly

GLP-1s, Hairlines, and the Almost-Pumpers: Why Modular Medical May Be Ready for Its Close-Up -( $LLY $MODD )

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

Diabesity’s New Plus‑One: FDA Gives Green Light to Modular Medical’s Pivot Patch Pump -( $MODD $LLY $NVO )

The Diabesity Gold Rush: GLP‑1 Giants and a Tiny Patch Pump Hunting for XXL Returns -( $AMGN GS $LLY $MODD $NVO )

The Big Mac Meets the Skinny Pill: How McDonald’s and Eli Lilly Are Sharing the Same Consumer -( $LLY $MCD )

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

Your Guide To Staying Informed In The Markets